Shaheen Urges Senate Vote on Insulin Cost Legislation

Senator Jeanne Shaheen’s Advocacy for Insulin Cost Cap

Senator Jeanne Shaheen (D-N.H.) is campaigning for a Senate vote on bipartisan legislation aimed at capping insulin costs for private insurance before the midterm elections. Her INSULIN Act proposes capping out-of-pocket insulin expenses at $35 for those with commercial insurance. This measure would extend a similar cap for Medicare recipients introduced through the Inflation Reduction Act in 2022. The proposed legislation also seeks to establish a pilot program in ten states to control insulin costs for uninsured individuals. Shaheen is retiring soon and aims to finalize the legislation before her tenure ends.

Senate Committee Support and Bipartisan Efforts

“President Trump campaigned on immediately lowering costs for the American people, yet he’s done just the opposite,” Shaheen stated. “With millions facing escalating prices due to this Administration’s health care policies, my INSULIN Act offers an immediate solution to lower costs for millions of Americans.”

Spearheaded by Shaheen, along with Senators Susan Collins (R-Maine), Raphael Warnock (D-Ga.), and John Kennedy (R-La.), the bill successfully passed the Senate Health Education, Labor and Pensions Committee with a 17-5 vote in July. It currently has 28 co-sponsors, equally shared between Democrats and Republicans, offering potential for 60 favorable votes in the Senate.

House Version and Bill Negotiations

A bipartisan House version was introduced earlier in the month by Representatives Diana DeGette (D-Colo.), Angie Craig (D-Minn.), Kim Schrier (D-Wash.), Mariannette Miller-Meeks (R-Iowa), and Rob Bresnahan (R-Pa.). Both Miller-Meeks and Bresnahan face tight reelection bids.

Despite support, the bill’s success is uncertain, as resistance persists over governmental influence in setting drug prices. Bill Cassidy (R-La.), Chair of the HELP committee, voted against the bill, criticizing it for creating an unnecessary government program. He argues that many community health centers already offer discounted insulin and condemns the federal drug pricing program for hospital exploitation.

Potential Legislative Pathways

While a Senate vote is improbable this week, strategic inclusion of the measure within a year-end spending bill remains likely. There is also consideration regarding its addition to the defense policy and spending authorization bill.

Related Healthcare Updates

Welcome to The Hill’s Healthcare newsletter, curated by Nathaniel Weixel and Joseph Choi, dedicated to highlighting how Washington affects your health. Here are some pivotal topics:

• Pennsylvania recently surpassed 900 measles cases, marking the highest number of infections in the U.S. according to the CDC.

• Senate Majority PAC launched a $2 million campaign against Sen. Susan Collins (R-Maine), focusing on Medicaid cuts attributed to her.

• Recall of 13,567 chlorthalidone tablet bottles from Inventia Healthcare Limited due to dissolving issues affecting dosage absorption.

Upcoming News Watch

• Nicole Saphier’s HELP Committee confirmation vote is pending.

Other News and Developments

• New SNAP benefits begin Oct. 1, affecting 37 million Americans.

• Growing 관심 for GLP-1s usage outside obesity treatment.

• Nationwide cheese recall due to E. coli outbreak.

• State initiatives for rural healthcare funding and constitutional amendments supporting reproductive health.

You’re caught up with today’s healthcare updates. Check back tomorrow!